- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharm Exec’s Pharma Top 50 in Brief
The vigorous return of M&A activity this year brings us back to the question: is more size and scalable efficiencies the best solution to the declining market power of pharmaceuticals in an endlessly restructuring healthcare system?
The vigorous return of M&A activity this year brings us back to the question: is more size and scalable efficiencies the best solution to the declining market power of pharmaceuticals in an endlessly restructuring healthcare system? Anecdotal evidence combined with some discomfiting statistics on pipeline productivity of the past 15 years suggests that the answer is no-and the latest Pharma 50 rankings bear this out.
Our one new entrant is South Africa's Aspen Pharmacare.
One of the clearest indicators of success is leadership in biologics and specialty drugs.
Biogen Idec has jumped to the 27th spot from 36th in 2010.
Gilead moves up to 18th in sales from 23rd in 2010.
Pfizer has ceded its top position for the first time since 2002.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
